CN104667200A - Pharmaceutical composition for treating schizophrenia - Google Patents

Pharmaceutical composition for treating schizophrenia Download PDF

Info

Publication number
CN104667200A
CN104667200A CN201510139683.3A CN201510139683A CN104667200A CN 104667200 A CN104667200 A CN 104667200A CN 201510139683 A CN201510139683 A CN 201510139683A CN 104667200 A CN104667200 A CN 104667200A
Authority
CN
China
Prior art keywords
parts
radix
rhizoma
pharmaceutical composition
polygoni multiflori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510139683.3A
Other languages
Chinese (zh)
Inventor
孙辉
王继委
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510139683.3A priority Critical patent/CN104667200A/en
Publication of CN104667200A publication Critical patent/CN104667200A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a pharmaceutical composition for treating schizophrenia. The pharmaceutical composition is prepared from the following raw materials: polygonum multiflorum, rhizoma acori graminei, polygala tenuifolia, herba epimedii, poria cocos, rheum officinale, red peony root, mangnolia officinalis, arisaema cum bile, centella, manyprickle acanthopanax root, rhizoma atractylodis macrocephalae, red rhodobryum, day lily, day lily, white paeony root, tuber fleeceflower stem, immature bitter orange, lalang grass rhizome, dendrobe, rhizoma anemarrhenae, rhizoma sparganii, pericarpium citri reticulatae, gardenia, curcuma aromatic and spina date seed. The pharmaceutical composition provided by the invention is capable of treating both symptoms and root causes of schizophrenia, is free of a side effect, low in price, simple and convenient to prepare, and wide in application prospect.

Description

One is used for the treatment of schizoid pharmaceutical composition
Technical field
The invention belongs to traditional Chinese medicine preparation technical field, concrete, relate to one and treat schizoid pharmaceutical composition.
Background technology
Schizophrenia is a kind of psychiatric condition, and be a kind of lasting, usually chronic great mental sickness, be one group of disease the most common in mental sickness.It is reported that the schizoid prevalence of China is up to 6.55 ‰, is the one that in mental sickness, prevalence is the highest.A lot of disease is in person between twenty and fifty, and normal slowly onset, has many-sided obstacles such as thinking, emotion, behavior, ergasia and environment inharmonious.Usually unconscious and disturbance of intelligence.The many delays of the course of disease, in repeatedly increasing the weight of or worsening.Each damage repeatedly brought is more and more serious, makes patient's personality change, and social adaptation declines, and causes disease refractory more, not only brings huge misery to patient, causes heavy financial burden also to family and society.
Schizoid clinical symptoms complexity is various, and can relate to the aspects such as sensory perception, thinking, emotion, volitional behavior and cognitive function, between individuality, symptom is widely different, even if same patient also may show different symptoms in different phase or stadium.(1) can there is multiple sensory perception obstacle in sensory perception obstacle schizophrenia, and the most outstanding sensory perception obstacle is hallucination, comprise auditory hallucination, photis, olfactory hallucination, gustatory hallucination and tactile hallucination etc., and auditory hallucination is the most common.(2) thought disturbance thought disturbance is schizoid core symptom, mainly comprises form of thinking obstacle and content of thought obstacle.Form of thinking obstacle for main manifestations, comprises the obstacle of thinking association active procedure (amount, speed and form), the thinking association aspect such as continuity and logicality with thinking associative process obstacle.Vain hope is the most common, most important content of thought obstacle.The vain hope the most often occurred has delusion of persecution, delusion of relation, delusion of influence, delusion of jealousy, the delusion of grandeur, non-descent delusion etc.According to estimates, delusion of persecution is there is up to the schizophrenic of 80%, delusion of persecution can show as insecurity in various degree, offerd medicine as being monitored, being ostracised, worry or murdered, under vain hope impact, patient can make defence or aggression, in addition, passive experience is also comparatively outstanding with it at some patients, has an impact to the thinking of patient, emotion and behavior.(3) the apathy and emotional responses of affective disorder is inharmonious is the modal affective symptom of schizophrenic, and in addition, the affective symptom such as incoordination excitement, irritability, depression and anxiety are also more common.(4) hypobulia of will and behavior disorder most of patients even lacks, show as movable minimizing, peel off and stay alone, behavior is passive, lack due enthusiasm and initiative, working and learning interest is gone down, is indifferent to future, to clearly not intending in the future, some patient may have some plans and intend, but seldom performs.(5) cognitive dysfunction incidence rate of cognitive defect in schizophrenic is high, and cognitive dysfunction appears in about 85% patient, as information processing and selective attention, working memory, short term memory and the cognitive defect such as study, n-back test.Certain dependency is there is between cognitive defect symptom and other psychotic symptoms, the cognitive defect symptom of patient as obvious in form of thinking obstacle is more obvious, the cognitive defect symptom of the obvious patient of negative symptoms is more obvious, and cognitive defect may be relevant with the generation of some positive symptom etc.Cognitive defect may betide psychotic symptoms clear before (as prodromal period), or sharply decline along with the appearance of psychotic symptoms, or extend along with the course of disease and progressively fail, tentatively think that Patients with Chronic Schizophrenia is more obvious than the cognitive defect of first episode schizophrenia.
At present both at home and abroad treatment schizophrenia Western medicine realizes the control to abnormal symptom with calm, sleeping being used for, as chlorpromazine, Tai Erdeng, the anti-piperazine of trifluoro etc., these medicines have certain therapeutic effect in the treatment, but are difficult to consolidate curative effect thus the phenomenon causing relapse rate high.Cause the general present situation of one " take medicine easily, drug withdrawal is difficult, easily calm, the difficult toxic and side effects of rehabilitation is large " thus, these drug side effectes are large simultaneously, have certain harm to brain and the heart, Liver and kidney function.Existing Chinese patent medicine prescription is simple, weak curative effect, still can not become the schizoid mainstream medicine for the treatment of.
Motherland's medical science thinks that schizophrenia belongs to the disease category such as Chinese medicine " demented ", " mania syndrome ", " dementia ".The traditional Chinese medical science thinks that its cause of disease and overaction of the five emotions, damaged by excess of seven emotions are relevant, or because of rage and fear, or unsuccessful because pondering over, or because having mixed feelings, all can cause the disorderly regulating YIN and YANG dysequilibrium of function, produces the pathological changes such as the stagnation of QI, expectorant are solidifying, pathogenic fire, blood stasis.Therefore, treatment is worked as with YIN and YANG balance regulating, and invigorating the spleen for dissipating phlegm, dispelling wind to relieve the exterior syndrome, clearing heart fire, blood circulation promoting and blood stasis dispelling is principle.
The object of this invention is to provide that a kind for the treatment of both the principal and secondary aspects of a disease, side effect are little, safe ready, cheap Chinese medicine composition.Its objective is to solve schizophrenia, overcome Western medicine toxic and side effects large, easily repeatedly, the inapparent problem of therapeutic effect, reaches the object for the treatment of both the principal and secondary aspects of a disease in drug withdrawal.
Summary of the invention
The defect that present inventor exists based on the schizoid medicine of existing treatment, by the research to Chinese medicine, and in conjunction with dialectical demonstration, in many ways the length of many families is collected, seek therapeutic regimen, from motherland's medical treasure-house, filter out YIN and YANG balance regulating, invigorating the spleen for dissipating phlegm, dispelling wind to relieve the exterior syndrome, the natural Chinese medicine of clearing heart fire, by theory of Chinese medical science prescription, skim the cream off milk, it is made to play to clear away heart-fire place tired, YIN nourishing and the production of body fluid promoting, to calm the nerves the effect nourished heart, adopt natural Chinese medicines raw material, through systematic study, scientific compatibility, meticulously be mixed with of the present invention for schizoid Chinese medicine composition in conjunction with Traditional Chinese Medicine technology, schizophrenia is had to effect of rapid healing.
For achieving the above object, the technical solution used in the present invention is as follows:
One is used for the treatment of schizoid pharmaceutical composition, it is characterized in that being prepared by following raw material and obtaining,
Radix Polygoni Multiflori, Rhizoma Acori Graminei, Radix Polygalae, Herba Epimedii, Poria, Radix Et Rhizoma Rhei, Radix Paeoniae Rubra, Cortex Magnoliae Officinalis, Arisaema Cum Bile, Herba Centellae, Radix Et Caulis Acanthopanacis Senticosi, the Rhizoma Atractylodis Macrocephalae, Rhodobryum roseum Limpr., Radix hemerocalis plicatae, Myrrha, the Radix Paeoniae Alba, Caulis Polygoni Multiflori, Fructus Aurantii Immaturus, Rhizoma Imperatae, Herba Dendrobii, the Rhizoma Anemarrhenae, Rhizoma Sparganii, Pericarpium Citri Reticulatae, Fructus Gardeniae, Radix Curcumae, Semen Ziziphi Spinosae.
Preferably, prepared by following weight proportioning raw material and obtain,
Radix Polygoni Multiflori 35 parts, Rhizoma Acori Graminei 35 parts, Radix Polygalae 35 parts, Herba Epimedii 35 parts, 30 parts, Poria,
Radix Et Rhizoma Rhei 30 parts, Radix Paeoniae Rubra 30 parts, Cortex Magnoliae Officinalis 30 parts, Arisaema Cum Bile 25 parts, Herba Centellae 25 parts,
Radix Et Caulis Acanthopanacis Senticosi 25 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Rhodobryum roseum Limpr. 20 parts, Radix hemerocalis plicatae 20 parts, Myrrha 20 parts,
The Radix Paeoniae Alba 18 parts, Caulis Polygoni Multiflori 18 parts, Fructus Aurantii Immaturus 18 parts, Rhizoma Imperatae 18 parts, Herba Dendrobii 15 parts,
The Rhizoma Anemarrhenae 15 parts, Rhizoma Sparganii 15 parts, Pericarpium Citri Reticulatae 10 parts, Fructus Gardeniae 10 parts, Radix Curcumae 10 parts, Semen Ziziphi Spinosae 5 parts.
Medicine of the present invention can add one or more pharmaceutically acceptable carriers and be mixed and made into any one clinically or pharmaceutically acceptable dosage form, preferred oral preparation.When being applied in the mode of oral administration the patient needing this treatment, conventional solid preparation can be made into, as tablet, capsule, soft capsule etc.
Preferably, its preparation method is:
(1) get Radix Polygoni Multiflori, Rhizoma Acori Graminei, Radix Polygalae, Herba Epimedii, Arisaema Cum Bile, Herba Centellae, Rhodobryum roseum Limpr., Caulis Polygoni Multiflori, Rhizoma Imperatae, Herba Dendrobii, Radix Curcumae mix in described ratio, add the ethanol relative to mixture 4-5 times amount 95%, reflux, extract, 3 times, each 2 hours, extracting solution merges, and is concentrated into the clear paste that density is 1.25g/ml, 80 DEG C of oven dry, be ground into powder, be complex A;
(2) get surplus stock medicine and add 3 times of water boiling and extraction twice, 1 hour first time, second time 0.5 hour, merge extracted twice liquid, it is the extractum of 1.25g/ml that extracting solution drying under reduced pressure is obtained density, after 80 DEG C of oven dry, is ground into powder, is complex B;
(3) by complex A and complex B mixing and stirring, sterilization obtains capsule product.
Chinese medicine YIN and YANG balance regulating of the present invention, dispelling wind to relieve the exterior syndrome, mind tranquilizing and the heart calming, reinforcing the heart of nourishing blood, tranquilizing the mind, waking up the patient from unconsciousness by clearing away phlegm nourishing the liver and kidney, have definite curative effect to schizophrenia, side effect is little.Fill blood, nourish heart kidney.
Usage and dosage: oral, a 0.2g, three times on the one.
Attention: hyperpietic avoids clothes, warm water delivery service.Period in a medicine avoids pungent food and cold and cool food, and avoid emotional stimulation, life is regular.
The present invention is used for schizoid Chinese patent medicine excellent results and is:
1. Chinese medicine preparation compatibility of the present invention meets Chinese medicine " monarch " principle, be made up of pure Chinese medicine, each component meets pharmaceutical control law regulation, utilize the comprehensive function of each taste Chinese medicine, not containing chemical components, not containing hormone, have no side effect, treating both the exterior and interior, reaches better enriching yin and nourishing kidney, tranquilizing by nourishing the heart effect;
2. this medicament short treating period, total effective rate is high, not easily recurs more.
3. technique of the present invention is simple, reduces production cost, alleviates the financial burden of patient.
Detailed description of the invention
Embodiment 1
One is used for the treatment of schizoid pharmaceutical composition, and it is prepared by following weight proportioning raw material and obtains,
Radix Polygoni Multiflori 35 parts, Rhizoma Acori Graminei 35 parts, Radix Polygalae 35 parts, Herba Epimedii 35 parts, 30 parts, Poria,
Radix Et Rhizoma Rhei 30 parts, Radix Paeoniae Rubra 30 parts, Cortex Magnoliae Officinalis 30 parts, Arisaema Cum Bile 25 parts, Herba Centellae 25 parts,
Radix Et Caulis Acanthopanacis Senticosi 25 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Rhodobryum roseum Limpr. 20 parts, Radix hemerocalis plicatae 20 parts, Myrrha 20 parts,
The Radix Paeoniae Alba 18 parts, Caulis Polygoni Multiflori 18 parts, Fructus Aurantii Immaturus 18 parts, Rhizoma Imperatae 18 parts, Herba Dendrobii 15 parts,
The Rhizoma Anemarrhenae 15 parts, Rhizoma Sparganii 15 parts, Pericarpium Citri Reticulatae 10 parts, Fructus Gardeniae 10 parts, Radix Curcumae 10 parts, Semen Ziziphi Spinosae 5 parts.
Its preparation method is:
(1) get Radix Polygoni Multiflori, Rhizoma Acori Graminei, Radix Polygalae, Herba Epimedii, Arisaema Cum Bile, Herba Centellae, Rhodobryum roseum Limpr., Caulis Polygoni Multiflori, Rhizoma Imperatae, Herba Dendrobii, Radix Curcumae mix in described ratio, add the ethanol relative to mixture 4 times amount 95%, reflux, extract, 3 times, each 2 hours, extracting solution merges, and is concentrated into the clear paste that density is 1.25g/ml, 80 DEG C of oven dry, be ground into powder, be complex A;
(2) get surplus stock medicine and add 3 times of soak by water twice, 1 hour first time, second time 0.5 hour, merge extracted twice liquid, it is the extractum of 1.25g/ml that extracting solution drying under reduced pressure is obtained density, after 80 DEG C of oven dry, is ground into powder, is complex B;
(3) by complex A and complex B mixing and stirring, sterilization obtains capsule product.
Chinese medicine YIN and YANG balance regulating of the present invention, dispelling wind to relieve the exterior syndrome, mind tranquilizing and the heart calming, reinforcing the heart of nourishing blood, tranquilizing the mind, waking up the patient from unconsciousness by clearing away phlegm nourishing the liver and kidney, have definite curative effect to schizophrenia, side effect is little.Fill blood, nourish heart kidney.
Usage and dosage: oral, a 0.2g, three times on the one.
Attention: hyperpietic avoids clothes, warm water delivery service.Period in a medicine avoids pungent food and cold and cool food, and avoid emotional stimulation, life is regular.
Embodiment 2
Acute toxicity testing: application mice 40, male and female half and half, body weight 30 ~ 40g, carries out acute toxicity test.Mice is divided into two groups at random, i.e. matched group and administration group group, often organize 20, fasting 12 hours before experiment, the Chinese patent medicine that administration group gives embodiments of the invention 1 preparation is dissolved in gastric infusion in water (gavage unit dosage form is 50g crude drug/kg), and matched group gives normal saline, administration in one day 2 times, delivery time 6 hours, Continuous Observation fortnight after administration, and record mice toxic reaction and death toll.Experimental result shows: compare with matched group, and after administration, mice has no notable difference, and experiment Continuous Observation 14 days, mouse systemic situation, diet, drinking-water, body weight increase all normal.Therefore Chinese patent medicine acute toxicity of the present invention is extremely low, clinical drug safety.
Long term toxicity test: respectively by Chinese medicine embodiment 1 capsule of the present invention to mice continuous use 10 weeks and drug withdrawal after 3 weeks, result shows: the index such as hair, behavior, defecation, body weight, organ weights, hemogram, hepatic and renal function, blood glucose, blood fat of Chinese medicine of the present invention to mice all has no significant effect, internal organs naked eyes do not find that difference change and histological indications show, medication 10 weeks and drug withdrawal are after 3 weeks, and Organs of Mice is all without obviously changing.Illustrate that Chinese medicine of the present invention is little to toxicity after mice long-term prescription, also there is no difference reaction after drug withdrawal, application safety.
Embodiment 3
1, clinical data
93 routine clinical patients chosen by clinical data, all meet schizoid diagnostic criteria in " Chinese Spirit Obstacles classification and diagnostic criteria ", wherein male 47 people, female 46 people, age 19-70 year, the course of disease 3 months to 28 years.
Diagnostic criteria: have following 2 at least, is not secondary to disturbance of consciousness, disturbance of intelligence, elation or low.(1) recurrent verbal auditory ballucination.(2) significantly thinking is loose, splitting of thought, the discontinuous or poverty of content of thought of speech.(3) thinking is inserted into and is withdrawn, and is sent out, and thinking is interrupted, or forced thinking.(4) controlled or known clearly experience.(5) vain hope of primary delusion (comprising delusional perception, Delusional mental state) or other waste slander.(6) thinking sieve collects perversion, morbid symbolic thinking or word new work.(7) parathymia; Or significantly feelings are puzzled indifferent.(8) stress syndrome, strange behavior or unwise behavior.(9), obvious hypobulia or shortage.
Therapeutic Method: give capsule preparations prepared by the embodiment of the present invention 1, oral, a 0.2g, three times on the one 1 month is 1 course for the treatment of.
Criterion of therapeutical effect:
Recovery from illness: symptom all disappears, and insight thoroughly recovers, to make comparisons deep understanding to the cognition of mental symptom as normal person.In dialogue, react and the pass of surrounding is fastened, level time healthy before reaching disease, can go to work normally work, study and process daily life.
Take a turn for the better: symptom disappears substantially, insight part is recovered, and substantially can take care of oneself, complete some work and study, but still has some gaps apart from normal person, need be maintained through a little medicine of informal dress.
Invalid: to continue drug administration symptom without improvement.
Therapeutic outcome: 93 routine patients are through the treatment of 1 ~ 5 course for the treatment of, and therapeutic effect is as shown in table 1 below:
Table 1
Number of cases Recovery from illness Take a turn for the better Invalid Total effective rate
Embodiment 1 93 59 28 6 93.5%
Conclusion: pharmaceutical composition of the present invention is evident in efficacy, and toxic and side effects is little, obtains good clinical efficacy.
Embodiment 4
Exemplary embodiments
Zhao, female, 38 years old.There is the symptoms of schizophrenia 3 years in patient, main manifestations is illusion, speaks ambiguous, top-heavy during morbidity, cannot walk, often have horrible nightmares, have a sleepless night, feel to have people key she.Once treated in a schizophrenia hospital, and took clozapine and sulpiride, symptom is not well controlled.After give embodiment 1 prepare pharmaceutical composition treated, family members are equipped with necessary psychology care and teach simultaneously, after 2 courses for the treatment of, patient mental's situation is obviously improved, have horrible nightmares simultaneously, number of times of having a sleepless night reduce, after continuing to take 1 month, the state of an illness is consolidated, and patient can carry out normal live and work.Follow up a case by regular visits to so far without recurrence.
Lee, man, 43 years old.Patient has schizophrenia 2 years medical histories, shows as and loses interest to various daily routines, apathy, and lose gradually and relatives and extraneous normally associate, the poverty of thought, loosening of associations, once took western medicine 1 year, but effect is undesirable.Give pharmaceutical composition prepared by embodiment 1, family members are equipped with necessary psychology care and teach simultaneously, and after 2 courses for the treatment of, family numbers of patients exchanges with it and finds to have clear improvement, and verbal expression skill strengthens; Continue to take one month, patient's thinking logic and language competence obviously progress, mental status improves greatly, can orthobiosis, and schizophrenia is cured substantially.Follow up a case by regular visits to so far without recurrence.
Above-mentioned each Chinese medicinal components that the present invention adopts makes compatibility mutually, its collaborative effect of curing the disease can be played, there is between each composition of raw material of Chinese medicine used drug effect be interweaved and mutually promote and coordinate usefulness, through clinical verification, have good therapeutic effect to schizophrenia, in the applicant's medical practice for many years, the case Numerous of curing, all obtains good effect, and with low cost, alleviate the burden of patient, have broad application prospects.

Claims (4)

1. be used for the treatment of a schizoid pharmaceutical composition, it is characterized in that, described pharmaceutical composition is prepared by following raw material and obtains,
Radix Polygoni Multiflori, Rhizoma Acori Graminei, Radix Polygalae, Herba Epimedii, Poria, Radix Et Rhizoma Rhei, Radix Paeoniae Rubra, Cortex Magnoliae Officinalis, Arisaema Cum Bile, Herba Centellae, Radix Et Caulis Acanthopanacis Senticosi, the Rhizoma Atractylodis Macrocephalae, Rhodobryum roseum Limpr., Radix hemerocalis plicatae, Myrrha, the Radix Paeoniae Alba, Caulis Polygoni Multiflori, Fructus Aurantii Immaturus, Rhizoma Imperatae, Herba Dendrobii, the Rhizoma Anemarrhenae, Rhizoma Sparganii, Pericarpium Citri Reticulatae, Fructus Gardeniae, Radix Curcumae, Semen Ziziphi Spinosae.
2. pharmaceutical composition according to claim 1, is characterized in that, described pharmaceutical composition is prepared by the raw material of following weight proportioning and obtains,
Radix Polygoni Multiflori 35 parts, Rhizoma Acori Graminei 35 parts, Radix Polygalae 35 parts, Herba Epimedii 35 parts, 30 parts, Poria,
Radix Et Rhizoma Rhei 30 parts, Radix Paeoniae Rubra 30 parts, Cortex Magnoliae Officinalis 30 parts, Arisaema Cum Bile 25 parts, Herba Centellae 25 parts,
Radix Et Caulis Acanthopanacis Senticosi 25 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Rhodobryum roseum Limpr. 20 parts, Radix hemerocalis plicatae 20 parts, Myrrha 20 parts,
The Radix Paeoniae Alba 18 parts, Caulis Polygoni Multiflori 18 parts, Fructus Aurantii Immaturus 18 parts, Rhizoma Imperatae 18 parts, Herba Dendrobii 15 parts,
The Rhizoma Anemarrhenae 15 parts, Rhizoma Sparganii 15 parts, Pericarpium Citri Reticulatae 10 parts, Fructus Gardeniae 10 parts, Radix Curcumae 10 parts, Semen Ziziphi Spinosae 5 parts.
3. the preparation method of pharmaceutical composition described in claim 1-2, is characterized in that, described preparation method comprises the steps:
(1) Radix Polygoni Multiflori, Rhizoma Acori Graminei, Radix Polygalae, Herba Epimedii, Arisaema Cum Bile, Herba Centellae, Rhodobryum roseum Limpr., Caulis Polygoni Multiflori, Rhizoma Imperatae, Herba Dendrobii, Radix Curcumae is got according to weight proportion, mixing, add the ethanol relative to mixture 4-5 times weight 95%, reflux, extract, 3 times, each 2 hours, extracting solution merged, be concentrated into the clear paste that density is 1.25g/ml, 80 DEG C of oven dry, are ground into powder, are complex A;
(2) get surplus stock, mixing, adds the water boiling and extraction twice of 3 times of weight, 1 hour first time, second time 0.5 hour, merges extracted twice liquid, and then drying under reduced pressure obtains density is the extractum of 1.25g/ml, after 80 DEG C of oven dry, be ground into powder, be complex B;
(3) by complex A and complex B mixing and stirring, sterilization and get final product.
4. the application of pharmaceutical composition described in claim 1-3.
CN201510139683.3A 2015-03-29 2015-03-29 Pharmaceutical composition for treating schizophrenia Pending CN104667200A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510139683.3A CN104667200A (en) 2015-03-29 2015-03-29 Pharmaceutical composition for treating schizophrenia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510139683.3A CN104667200A (en) 2015-03-29 2015-03-29 Pharmaceutical composition for treating schizophrenia

Publications (1)

Publication Number Publication Date
CN104667200A true CN104667200A (en) 2015-06-03

Family

ID=53303136

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510139683.3A Pending CN104667200A (en) 2015-03-29 2015-03-29 Pharmaceutical composition for treating schizophrenia

Country Status (1)

Country Link
CN (1) CN104667200A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335690A (en) * 2002-05-20 2003-11-25 Fancl Corp Composition having affinity to receptor
CN104083608A (en) * 2014-06-03 2014-10-08 王春芳 Traditional Chinese medicine preparation for treating schizophrenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335690A (en) * 2002-05-20 2003-11-25 Fancl Corp Composition having affinity to receptor
CN104083608A (en) * 2014-06-03 2014-10-08 王春芳 Traditional Chinese medicine preparation for treating schizophrenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
罗诚等: "中医辨证治疗精神分裂症82例", 《陕西中医》 *

Similar Documents

Publication Publication Date Title
CN101444611B (en) Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof
CN101773650A (en) Chinese medicinal composition for treating clonic convulsion and preparation method thereof
CN105194631A (en) Traditional Chinese medicine preparation for treating depression
CN105327287A (en) Pharmaceutical composition for treating psychosis and preparation technology thereof
CN104274789A (en) Traditional Chinese medicine composition for treating depression
CN105769789A (en) Clozapine tablets for treating schizophrenia and preparation method thereof
CN105497261A (en) Matrix of patch for external use and patch and sleeping-aid patch made from matrix
CN104667199A (en) Pharmaceutical preparation for treating mental anxiety and application of pharmaceutical preparation
CN102698058A (en) Health care extract for adjusting sub-healthy state of human body
CN104383421A (en) Pharmaceutical preparation for treating insomnia and dreaminess
CN104383420A (en) Preparation method of pharmaceutical preparation for treating insomnia and dreaminess
CN103638336B (en) Full rhizoma gastrodiae tablet
CN104740581B (en) A kind of application of cold asthma patch of fragrant fiber crops and its detection method
CN103784893B (en) A kind of medicine for the treatment of cerebral apoplexy sequela
CN104667200A (en) Pharmaceutical composition for treating schizophrenia
CN104352973A (en) Chinese patent medicine for postpartum depression
CN105902967A (en) Compound pharmaceutical preparation for psychosis
CN104352688A (en) Traditional Chinese medicine formula for stopping novel drug addiction and carrying out rehabilitation treatment on sequelae and preparation method thereof
CN104740579B (en) Premenstrual peace piece and its preparation technology
CN102949656A (en) Health care product capsule used for preventing and treating depression and preparation method thereof
CN102441103A (en) Medicine for treating insomnia
CN105853942A (en) Medicine preparation for treating schizophrenia and preparation method thereof
CN102225132A (en) Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof
CN104383441A (en) Method for preparing Chinese patent medicine for treating postpartum depression
CN104587396A (en) Preparation for preventing dizziness caused by power overhead operation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150603